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Background: Postoperative atrial fibrillation (POAF) is one of the most common complications in patients
undergoing coronary artery bypass grafting (CABG). The goal of this meta-analysis was to evaluate the efficacy of
thoracic epidural anesthesia (TEA) in preventing POAF in adult patients undergoing CABG.
Methods: MEDLINE and EMBASE were searched to identify randomized controlled trails in adult patients
undergoing CABG who were randomly assigned to receive general anesthesia plus thoracic epidural anesthesia
(GA + TEA) or general anesthesia only (GA). Two authors independently extracted data using a standardized Excel
file. The primary outcome measure was the incidence of POAF. We used DerSimonian-Laird random-effects models
to compute summary risk ratios with 95% confidence intervals.
Results: Five studies involving 540 patients met our inclusion criteria. No significant difference in the incidence of
POAF was observed between the two groups (risk ratio, 0.61; 95% confidence interval, 0.33 to 1.12; P= 0.11), with
significant heterogeneity among the studies (I2 = 73%, P= 0.005). Sensitivity analyses by primary endpoint,
methodological quality and surgical technique yielded similar results.
Conclusions: The limited evidence suggests that TEA shows no beneficial efficacy in preventing POAF in adult
patients undergoing CABG. However, the results of this meta-analysis should be interpreted with caution due to
significant heterogeneity of the studies included. Thus, the potential infuence of TEA on the incidence of atrial
fibrillation following CABG warrants further investigation.
Keywords: Thoracic epidural anesthesia, Postoperative atrial fibrillation, Meta-analysisBackground
Postoperative atrial fibrillation (POAF) is one of the
most common complications encountered after CABG.
The incidence of POAF reported in previous studies var-
ies between 20% and 40%, depending on definitions and
methods of detection [1-3]. Although the majority of
POAF are benign and self-limiting, it has been shown to
increase both the length of hospital stay and total hos-
pital costs significantly [4,5]. Thus, the prevention of* Correspondence: yinruixing@yahoo.com.cn
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reproduction in any medium, provided the orPOAF is of great importance. In recent decades, many
pharmacologic interventions have been used to prevent
the development of POAF, for example, β-blockers, sota-
lol, amiodarone, and magnesium [6]. However, all of
them have limited effectiveness and are not free of side
effects. The limited efficacies of pharmacologic interven-
tions have stimulated research into alternative prophy-
lactic strategies to prevent POAF.
The etiology of POAF is not widely known and has
been related to many risk factors [7]. Increased sympa-
thetic activation appears to be important in the patho-
genesis of POAF [8]. As TEA reduces sympathetic
activity, it seems to be a promising non-pharmacologic
intervention to reduce the incidence of POAF and couldThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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arrhythmias [9]. However, the studies regarding TEA in
preventing POAF conveyed mixed and inconclusive
results [10-19]. We therefore performed a meta-analysis
based on relevant randomized controlled trials to evalu-
ate the efficacy of TEA in preventing POAF in adult
patients undergoing CABG.
Methods
Literature search and selection criteria
MEDLINE and EMBASE (up to March 1, 2012) were
searched for randomized controlled trails in adult
patients undergoing CABG who were randomly assigned
to receive GA+TEA or GA only. Search terms included
“thoracic epidural” and “coronary artery”. No language
restriction was imposed. The searches were limited to
human subjects and randomized controlled trials. In
addition, reference lists from the identified articles were
manually examined for relevant new articles. This
process was performed iteratively until no additional
articles could be identified.
We included studies in all languages irrespective of
blinding when the following inclusion criteria were met:
enrolled adult patients (i.e., 18 yr or older) undergoing
CABG; randomly assigned to receive GA+TEA or GA
only; reported data on the incidence of POAF; and pro-
vided definition and monitoring of POAF. Tials were
excluded if they enrolled patients 1) requiring salvage
CABG, 2) undergoing CABG and valve surgery at the
same time, 3) existing preoperative atrial fibrillation.
Data extraction and quality assessment
Two authors (WJG and CYW) independently extracted
data from all eligible studies using a standardized Excel
file. The following data were extracted from each
study: first author’s last name, year of publication,
number of enrolled patients, surgery type, CABG tech-
nique, perioperative management of TEA, the defin-
ition and monitoring methods of POAF, and outcome
data. Any disagreements were resolved by discussion
and consensus.
We assessed the methodological quality of included
RCTs using the Jadad scale [20]. The scale consists of
three items describing randomization (0–2 points),
blinding (0–2 points), and dropouts and withdrawals (0–1
points) in the report of a randomized controlled trial. A
score of 1 is given for each of the points described. A
further point is obtained where the method of
randomization and/or blinding is given and is appropri-
ate; whereas it is inappropriate a point is deducted.
Higher scores indicate better reporting. The quality scale
ranges from 0 to 5 points. The studies are said to be of
low quality if the Jadad score is ≤2 and high quality if
the score is ≥3 [21].Statistical analysis
We assessed the overall efficacy of TEA in preventing
POAF based on the data from included 5 RCTs. The in-
cidence of POAF was treated as dichotomous variables
and was expressed as risk ratio (RR) with 95% confi-
dence interval (CI) for each study.
Heterogeneity across studies was tested by using
the I2 statistic, which is a quantitative measure of in-
consistency across studies. Studies with an I2 statistic
of 25% to 50% are considered to have low heterogen-
eity, those with an I2 statistic of 50% to 75% are con-
sidered to have moderate heterogeneity, and those
with an I2 statistic of >75% are considered to have a
high degree of heterogeneity [22]. I2 less than 50%
has been considered as nonimportant heterogeneity
[23]. In case of important heterogeneity, we used the
random-effects model. We further conducted sensi-
tivity analyses to assess the robustness of our results
and to explore the potential sources of heterogeneity.
Sensitivity analyses were done according to the fol-
lowing: (1) primary endpoint; (2) methodological
quality; and (3) CABG technique.
Potential publication bias was evaluated by inspecting
funnel plots and performing Begg and Egger tests
[24,25]. A two-tailed P-value of less than 0.05 was
judged as statistically significant. All statistical analyses
were performed using Review Manager, Version 5.0 (The
Nordic Cochrane Centre, The Cochrane Collaboration;
Copenhagen, Denmark).
Results
Identification of eligible studies
A total of 97 studies were identified by the initial data-
base search. Thirty-five studies were excluded because of
duplicate studies and 20 studies were excluded based on
the titles and abstracts. After detailed assessment, 32
studies were excluded because they did not meet our in-
clusion criteria. For the remaining 10 RCTs, five of these
were also excluded because POAF was not well defined
and the monitoring of POAF was not specified clearly
[10-14]. Finally, five RCTs that met our inclusion criteria
were included in the present meta-analysis [15-19]. The
flowchart of studies included in meta-analysis was
shown in Figure 1.
Study characteristics
The summary of RCTs included in the meta-analysis is
shown in Table 1. These studies were published between
2001 and 2009. The size of the RCT ranged from 50 to
163 (total 540). Three studies in this meta-analysis en-
rolled patients undergoing CABG with CPB technique
[15,16,18], the remaining two studies included patients
undergoing CABG with OPCAB technique [17,19]. The
quality of the included studies was assessed by the Jadad
Figure 1 Selection Process for RCTs Included in the Meta-analysis. CABG, coronary artery bypass grafting; POAF, postoperative atrial
fibrillation; RCT, randomized controlled trials.
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was 3 (range from 2 to 3).
TEA and POAF
The definition and monitoring of POAF in the various
studies are summarized in Table 2. Overall, 540 patients
were included in this analysis (247 in the TEA+GA
group and 293 in the GA only group). Meta-analysis of
5 studies using a random-effects model suggested that
TEA had no significant effect on the prevention of
POAF (RR 0.61, 95% CI 0.33 to 1.12; P= 0.11; Figure 2).
There was significant heterogeneity among the studies
(I2 = 73%, P= 0.005; Figure 2).
Sensitivity analyses
Subsequently, we performed sensitivity analyses to ex-
plore the source of this heterogeneity and to examine
the influence of various exclusion criteria on the com-
bined estimates. Exclusion of 2 studies in which POAF
did not served as the primary endpoint yielded similar
results (RR 0.64, 95% CI 0.26 to 1.58; P= 0.33), with sub-
stantial evidence of heterogeneity (I2 = 82%, P= 0.004)
[18,19]. After exclusion of 2 studies with low-quality
studies (Jadad score ≤ 2), the results were still maintained
(RR 0.73, 95% CI 0.37 to 1.44; P= 0.36), yet heterogen-
eity was still present (I2 = 68%, P= 0.04) [15,17].Exclusion of 2 studies that conducted in patients under-
going CABG with OPCAB technique did not change the
pooled results (RR 0.98, 95% CI 0.72 to 1.35; P= 0.92),
but no evidence of heterogeneity was observed among
the remaining studies (I2 = 0%, P= 0.44) [17,19].
Publication bias
Publication bias was not assessed because of the limited
number (below 10) of studies included in each analysis.
Discussion
In the present meta-analysis, we have reviewed the lit-
erature regarding the efficacy of TEA in preventing
POAF in adult patients undergoing CABG. The pooled
results from meta-analysis of five RCTs using a random-
effects model suggest that TEA shows no beneficial effi-
cacy in preventing POAF in adult patients undergoing
CABG. Also, substantial heterogeneity across the studies
was observed.
The main finding of our meta-analysis seems to contra-
dict a previous review on the topic, which assessed the
effects of TEA on the clinical outcomes in patients
undergoing cardiac surgery. In detail, in a meta-analysis
by Svircevic et al. [26], it was noted that “the use of TEA
in patients undergoing cardiac surgery reduces the risk
of postoperative supraventricular arrhythmias.” In fact,


















Jidéus/2001 [15] 121 elective CABG CPB Unclear T2-T5, the day
before surgery
Intraoperative: bupivacaine 5 mg/mL,
with an infusion rate of 4 to 8 mL/h.
Postoperative: continuous infusion of
bupivacaine (2 mg/mL) and sufentanil
(1 mg/mL) epidurally (3 to 7 mL/h)
Yes 13/41 29/80 RCT/2
Nygard/2004 [16] 163 elective CABG CPB 4 days T1-T3, the day
before surgery
Intraoperative and postoperative :
bolus doses of 4 mL of bupivacaine,
5 mg/mL, given hourly
Yes 28/79 25/84 RCT/3
Bakhtiary/2007 [17] 132 elective CABG OPCAB 3 days T1-T3, the day
before surgery
Preoperative and postoperative:
continuous infusion with ropivacaine
0.16 % and sufentanil 1 g/mL at an
hourly rate of 2 to 5 mL was started
after a bolus dose of 6 mL
Yes 2/66 18/66 RCT/2
Tenenbein/2008 [18] 50 elective or
semi-elective
CABG




Intraoperative: 5-mL bolus of 0.75%
ropivacaine and 200 μg of hydromorphone
in the epidural catheter, followed by
infusion of 0.75 % ropivacaine at 5 mL/h.
Postoperative: continuous infusion lasting
48 h and consisting of 0.2 % ropivacaine,
with 15 μg/mL of hydromorphone titrated.
No 6/25 9/25 RCT/3
Caputo/2009 [19] 74 elective CABG OPCAB 3 days T2-T4, before
induction of
anesthesia
Intraoperative and postoperative: continuous
infusion of 0.125 % bupivacaine and
0.0003 % clonidine (150 g in 500 mL) at an
initial rate of 10 mL/h
No 7/36 18/38 RCT/3





















Table 2 Definition and monitoring of POAF used in the included trials of the meta-analysis
First author/Year of publication Definition of POAF Monitoring of POAF
Jideus/2001 [15] The absence of consistent P waves before each QRS
complex and with an irregular ventricular rate,
lasting 30 seconds or longer
Twenty-four hour Holter ECG performed on the
first 4 consecutive days, or until clinically
documented sustained atrial fibrillation
Nygard/2004 [16] New-onset atrial fibrillation (irrespective of treatment),
an irregular narrow complex rhythm with absence
of P waves
Twenty-four hour Holter ECG performed on the
first 5 consecutive days
Bakhtiary/2007 [17] An episode of atrial fibrillation or flutter lasting for
more than 30 seconds
Continuous ECG performed for 48 hours, then,
twice daily 12-lead ECG performed until
hospital discharge
Tenenbein/2008 [18] A need for pharmacologic treatment Holter ECG performed on the first three
postoperative days
Caputo/2009 [19] New onset of atrial fibrillation not present preoperatively Continuous ECG performed in the intensive care
unit, high-dependency unit, and ward, and daily
12-lead ECG analysis
POAF, postoperative atrial fibrillation; ECG, electrocardiogram.
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clearly emphasized, the included studies were heteroge-
neous and the study by Scott et al. [27] in 420 patients
mainly contributed to this result. In this study, all
patients discontinued β-blockers therapy during the
study period. Moreover, the patients in TEA+GA group
received clonidine, while the patients in GA group were
not given this cardioprotective drug [28]. The above fac-
tors may result in the beneficial efficacy of TEA on
supraventricular arrhythmias.
For the current meta-analysis, we evaluated the effi-
cacy of TEA in preventing POAF in adult patients
undergoing CABG. In an attempt to produce robust
results, we pre-stated rigorous inclusion criteria and
included only RCTs that provided definition and moni-
toring of POAF. We found that there was no significant
difference in the incidence of POAF between the two
groups, but significant heterogeneity was observed
among these studies. Our sensitivity analyses suggest
that 2 studies conducted in patients undergoing CABG
with OPCAB technique probably contributed to the he-
terogeneity [17,19]. In addition, sensitivity analyses based
other various exclusion criteria did not materially alter
the pooled results, which added robustness to our main
finding.Figure 2 Forest plot for the incidence of POAF. There were no signific
effects model. RR, relative risk; CI, confidence interval.Our study provides additional interesting clues that
may be useful for future research on the topic. Two
RCTs included in our meta-analysis were conducted in
patients undergoing CABG with OPCAB technique in-
stead of CPB [17,19]. These two studies consistently sug-
gest that TEA+GA significantly reduced the incidence
of POAF. Thus, a new question arise, does TEA really
reduce the incidence of POAF in patients undergoing
CABG with OPCAB technique? However, a recent
meta-analysis indicated that OPCAB technique was
associated with lower incidence of POAF when com-
pared with CPB technique in the population undergoing
CABG [29]. Besides, in one study [17], the patients in
the TEA group received ropivacaine which has a sub-
stantial anti-inflammatory effect [30]. In the other study
[19], the epidural infusion protocol used was similar to
the one used by Scott and colleagues [27] and clonidine
was administered only to the patients in TEA group.
These may make the isolated effects of TEA on the inci-
dence of POAF become less clear and raise additional
concerns on the interpretation of the positive results.
One could expect that use of TEA may cause potential
complications in patients undergoing CABG. TEA may
give rise to the following possible hazardous complica-
tions, such as the appearance of epidural hematoma.ant effects in preventing POAF as determined by the random-
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monary bypass could increase the incidence of epidural
hematoma related to the use of an epidural catheter
[31]. In addition, the intense sympathycolysis may lead
to systemic hypotension, which can be difficult to cor-
rect. In the included studies, no cases of epidural
hematoma were reported because this devastating com-
plication is too rare to evaluate in randomized studies.
Additional studies or data regarding the potential com-
plications related to TEA are warranted.
There are several potential limitations that should be
taken into account. First, substantial heterogeneity
among studies was observed. Nevertheless, we were able
to detect the major source of heterogeneity through the
sensitivity analyses. Second, our analysis was based on
only five RCTs and all of them were carried out in only
western countries and just enrolled older age patients
undergoing elective surgery. Thus, the results of the
RCTs need to be reproduced in other populations. Mor-
ever, we only included the trial providing definition and
monitoring of POAF. Because the end-point of our study
was less POAF, the monitoring needs to specificied
clearly for the various studies. Since identification of
POAF is critical to the conclusion, the monitoring has
to be standardized or at least specified. Otherwise the
conclusions are hard to justify. Exclusion of the studies
lacking a clear definition of POAF may have potential
influence on the final analysis. Finally, these studies lack
homogeneity in both the method of postoperative moni-
toring and in their definition of POAF. This may lead to
potential underestimation and/or overestimation of the
true incidence of POAF.
Conclusion
In summary, the limited evidence suggests that TEA
shows no beneficial efficacy in preventing POAF in
adult patients undergoing CABG. However, the
results of this meta-analysis should be interpreted
with caution due to significant heterogeneity of the
studies included. Thus, the potential infuence of TEA
on the incidence of atrial fibrillation following CABG
warrants further investigation.
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